Fisher Scientific customers and collaborators can expect the firm to continue to make acquisitions to bolster its life sciences portfolio — particularly its reagent play — as it aims to capitalize on a strong cash position.

Over the past two years, Fisher has entered the RNAi and cell-screening markets through its purchases of Dharmacon and Cellomics, respectively (see BioCommerce Week 8/11/2005).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.